Schedule of Financial Information by Segment (Details) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2024 |
Sep. 30, 2023 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Dec. 31, 2022 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| Segment Reporting Information [Line Items] | |||||||||
| Net revenues | $ 9,296,000 | $ 3,786,000 | $ 36,088,000 | $ 10,659,000 | $ 22,771,000 | $ 17,975,000 | |||
| Gross profit | 6,755,000 | (1,690,000) | |||||||
| Direct expenses | 16,565,000 | 16,212,000 | 56,143,000 | 92,565,000 | 81,041,000 | 144,198,000 | |||
| Segment contribution | (11,152,000) | (16,028,000) | (27,701,000) | (88,313,000) | (74,286,000) | (145,888,000) | |||
| Indirect expenses | 375,000 | 83,228,000 | 1,377,000 | 117,289,000 | 118,001,000 | (120,288,000) | |||
| Loss from operations | (11,527,000) | (99,256,000) | (29,078,000) | (205,602,000) | (192,287,000) | (25,600,000) | |||
| Change in fair value of contingent consideration liability | (104,339,000) | (104,339,000) | (126,277,000) | ||||||
| Goodwill impairment | 82,714,000 | $ 0 | $ 29,633,000 | $ 3,610,000 | 112,347,000 | 112,347,000 | 3,610,000 | ||
| IPR&D impairment | 107,800,000 | 107,800,000 | |||||||
| Change in fair value of contingent stock consideration | (159,000) | (159,000) | 186,000 | ||||||
| Cost of revenues (excluding amortization of acquired intangible assets) | 3,883,000 | 3,602,000 | 7,646,000 | 6,407,000 | |||||
| Cell Therapy [Member] | |||||||||
| Segment Reporting Information [Line Items] | |||||||||
| Net revenues | |||||||||
| Gross profit | |||||||||
| Direct expenses | 3,496,000 | 4,887,000 | 12,383,000 | 53,505,000 | 28,694,000 | 75,379,000 | |||
| Segment contribution | (3,496,000) | (4,887,000) | (12,383,000) | (53,505,000) | (28,694,000) | (75,379,000) | |||
| Cost of revenues (excluding amortization of acquired intangible assets) | |||||||||
| Biobanking [Member] | |||||||||
| Segment Reporting Information [Line Items] | |||||||||
| Net revenues | 1,292,000 | 1,427,000 | 3,857,000 | 4,062,000 | 5,441,000 | 5,512,000 | |||
| Gross profit | 3,791,000 | 1,976,000 | |||||||
| Direct expenses | 353,000 | 350,000 | 1,216,000 | 780,000 | 1,752,000 | 1,699,000 | |||
| Segment contribution | 701,000 | 679,000 | 1,689,000 | 1,927,000 | 2,039,000 | 277,000 | |||
| Cost of revenues (excluding amortization of acquired intangible assets) | 238,000 | 398,000 | 952,000 | 1,355,000 | |||||
| Degenerative Disease [Member] | |||||||||
| Segment Reporting Information [Line Items] | |||||||||
| Net revenues | 8,004,000 | 2,359,000 | 32,231,000 | 6,597,000 | 17,330,000 | 12,463,000 | |||
| Gross profit | 2,964,000 | (3,666,000) | |||||||
| Direct expenses | 4,187,000 | 1,901,000 | 14,385,000 | 6,799,000 | 9,720,000 | 10,859,000 | |||
| Segment contribution | 172,000 | (2,746,000) | 11,152,000 | (5,254,000) | (6,756,000) | (14,525,000) | |||
| Cost of revenues (excluding amortization of acquired intangible assets) | 3,645,000 | 3,204,000 | 6,694,000 | 5,052,000 | |||||
| Other [Member] | |||||||||
| Segment Reporting Information [Line Items] | |||||||||
| Net revenues | |||||||||
| Gross profit | |||||||||
| Direct expenses | 8,529,000 | 9,074,000 | 28,159,000 | 31,481,000 | 40,876,000 | 56,261,000 | |||
| Segment contribution | (8,529,000) | (9,074,000) | (28,159,000) | (31,481,000) | (40,876,000) | (56,261,000) | |||
| Indirect expenses | 375,000 | 83,228,000 | 1,377,000 | 117,289,000 | 118,001,000 | (120,288,000) | |||
| Change in fair value of contingent consideration liability | (39,000) | (104,339,000) | (104,339,000) | (126,277,000) | |||||
| Goodwill impairment | 82,714,000 | 112,347,000 | 112,347,000 | 3,610,000 | |||||
| IPR&D impairment | 107,800,000 | 107,800,000 | |||||||
| Amortization | 375,000 | 553,000 | 1,377,000 | 1,640,000 | 2,193,000 | 2,193,000 | |||
| Total other | 375,000 | 83,228,000 | 1,377,000 | 117,289,000 | $ 118,001,000 | (120,288,000) | |||
| Change in fair value of contingent stock consideration | (159,000) | $ 186,000 | |||||||
| Cost of revenues (excluding amortization of acquired intangible assets) | |||||||||